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Abstract 
It is now well accepted that the NF-B pathways are in-
volved in inflammatory diseases, cancer development 
and progression in human solid tumors. The NF-B signaling  
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element IB  was shown to inactivates NF-B activity 
through sequestration of this transcription factor in the 
cytoplasm. In the present study, we investigated the im-
pact of the IB on the invasive growth of human colon 
cancer cells HCT8/S11 stably transfected by this endoge-
nous NF-B inhibitor. We report that IB ectopic expres-
sion inhibited NF-B promoter activity induced by the 
Y527Fsrc oncogene, and reduced HCT8/S11 cell migration 
in wound healing assays. Our data show that IB 
 abrogated collagen type I invasion induced by the trefoil 
factors TFF1 and TFF3, but was ineffective on the invasive 
phenotype determined by leptin. Moreover, IB  reduced 
HCT8/S11 cell proliferation in vitro and the growth of their 
corresponding tumor xenografts established in the 
athymic mice. Taken together our data demonstrated 
that the intrinsic NF-B inhibitor IB negates several trans-
forming functions in human colon cancer cells. Our data 
provide the rationale for further preclinical and clinical 
studies based on therapeutic interventions targeting NF-B 
pathway. 
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Introduction 
 Cancer is the third leading cause of death 
in the United Arab Emirates (UAE) and other 
major World regions1. Despite recent progress 
in the treatment of human solid tumors and 
leukemia, new strategies leading to the design 
of targeted anticancer drugs are expected to 
improve cancer patient survival. Nuclear NF-
B is a key transcription factor involved in nor-
mal development, inflammatory diseases, and 
cancer progression2. In many types of cancers 
including breast and colon cancer, the 
transcription factor NF-B is constitutively 
activated3 ,4. The activity of NF-B is regulated 
by the IB proteins, which bind NF-B and re-
tains it in the cytoplasm. Thus, IB-inhibitor of 
NF-B, induces the formation of the inactive 
heterotrimeric complex comprising p50/p65 
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and IB. Upon cellular stimulation, IB is phos-
phorylated by the IB kinase (IKK), ubiquiti-
nated and degraded by the proteasome, 
allowing the nuclear translocation of the 
p50/p65 NF-B complex to regulate transcrip-
tion of diverse genes encoding cytokines, 
growth factors, cell adhesion molecules, and 
regulators involved in survival and apoptosis5 ,6. 
Consistently, NF-B activation is associated 
with transient and chronic inflammatory states 
linked to tumor promotion, progression and 
metastasis in several mouse models and clini-
cal situations7. 
 Loss-of-function mutations in IB-, resulting 
in high constitutive nuclear activity of NF-B, 
are characteristic of Reed–Sternberg cells in 
Hodgkin lymphoma8 ,9. This implies a tumor 
suppression function for IB. Moreover, defec-
tive  were found in several solid tumors 
such as colon, breast, ovarian, pancreatic, 
bladder, prostate carcinomas and mela-
noma10. While ubiquitination-mediated prote-
olysis of IB by the 26S proteasome leads to 
NF-B activation11, proteolysis of IB by 
caspase 3 inhibited NF-B activation instead. 
This proteolysis generated an N-terminal trun-
cated protein that can still bind to NF-B and is 
resistant to TNF-induced phosphorylation and 
degradation12. Interestingly, phosphorylation 
of IB by IKK or replacement of Ser32 and 
Ser36 with glutamates to mimic their phos-
phorylation prevented caspase-mediated 
proteolysis13. It appears then that phosphoryla-
tion of IB by IKK serves for proteasome-
dependent proteolysis of IB, and avoids 
generation of a repressor-like fragment of IB  
by caspases.  
 In the present study, we investigated the 
impact of IB ectopic expression on several 
transforming functions explored in the 
HCT8/S11 human colonic cancer cell line. We 
examined the behavior of IB -transfected 
HCT8/S11 cells on cell proliferation, migration 
and invasion assays monitored in vitro with the 
proinvasive agents trefoil factors TFF1, TFF3, 
and leptin14 ,15. In addition, we examined the 
influence of IB on the growth of HCT8/S11 
tumor xenografts established in immunodefi-
cient mice. 
Materials and Methods 
Cell Culture, NF-B Gene Reporter Assays, and 
Stable Transfections  
 Human colorectal cancer cells HCT8/S11 
were cultured in RPMI 1640 (Invitrogen, Cergy 
Pontoise, France) supplemented with 10% fetal 
bovine serum (Roche Molecular Biochemi-
cal’s, Meylan, France). For transient transfec-
tions, HCT8/S11 colonic epithelial cells were 
seeded in six-well plates at a density of 75,000-
200,000 cells/well. After overnight adhesion, 
cells were transfected with the Luciferase re-
porter constructs driven by NF-B -dependent 
promoter, using the LipofectAMINE Reagent 
(Invitrogen). Where indicated, the transfection 
mixture was combined with plasmid vectors 
encoding src and IB. The src expression vec-
tor pSGT-srcY527F encoding the src oncogene 
and the corresponding control empty plasmid 
pSGT were provided by Dr. Serge Roche 
(CNRS UPR-1086 CRBM, Montpellier, France). 
Before assaying for luciferase activity, cells 
were washed with cold phosphate buffered 
saline (PBS) and scraped in the luciferase lysis 
buffer. Luciferase assays were performed using 
the Luciferase Assay System (Promega, Madi-
son, USA). Values shown are mean ± SEM of at 
least three independent experiments, each 
performed in triplicate. 
 For stable transfections, HCT8/S11 cells were 
plated for 24h in 60 mm culture dishes and 
transfected by lipofection (LipofectAMINE 
Reagent Plus, Invitrogen), according to the 
manufacturer's instructions. Cells were trans-
fected with 4μg of the expression vector 
pECFP-IB carrying the neomycin resistance 
gene. The expression vector pECFP-IB was a 
gift from Dr. Johannes A. Schmid (Department 
of Vascular Biology and Thrombosis Research, 
University Vienna, Austria). The next day, cul-
tures were split into two 100-mm-diameter 
dishes and selected for ten days in the culture 
medium supplemented with 400 μg/ml of 
G418. Resistant colonies were ring-cloned as 
individual clones or pooled. Expression of the 
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transgene was determined by Western blot-
ting using the IB  mouse monoclonal anti-
body H4 raised against the GST-IB   human 
fusion protein (Santa Cruz, CA, USA). 
Wound Healing and Invasion Assays 
 Cells were grown in six-well culture dishes 
until confluence and then incubated for 10 
min in Moscona buffer (137 mM NaCl, 2.68 mM 
KCl, 11.9 mM NaHCO3, 9.43 mM glucose, 0.176 
mM NaH2PO4), pH7.4. The buffer was sterilized 
by filtration through a 0.22μm filters and stored 
at -20°C until use. A scrape was made through 
the confluent monolayer with a plastic pipette 
tip of 1mm diameter, the Moscona buffer was 
removed, and the dishes were washed twice 
and incubated at 37°C in fresh RPMI contain-
ing 10% fetal calf serum. At the underside of 
each dish, a mark was made at three arbitrary 
places where the width of the wound was 
measured with an inverted microscope (ob-
jective x 4). Migration was expressed as the 
average ± SEM of the difference between the 
measurements at time zero and the time 
points 4h, 6h, and 48h. The complete healing 
of the wound corresponds to 100%. The heal-
ing index corresponds to the % of the wound 
that is repaired per unit of time (h). 
 For invasion of collagen gels by HCT8/S11 
and HCT8/S11- IB  cells, six-well tissue culture 
dishes were filled with 1.35 ml of neutralized 
type I collagen (Upstate Biotechnology, Lake 
Placid, NY) and incubated overnight at 37°C 
to allow gelling. Parental and HCT8/S11- IB 
cells were harvested using Moscona buffer 
and trypsin/EDTA, and seeded on top of the 
collagen gels at the density of 300,000 cells 
per dish. Cultures were incubated for 24h at 
37°C, in the presence or absence of the indi-
cated agents. The number of invasive and 
superficial cells were counted in 12 fields of 
0.157 mm2 using an inverted microscope. The 
invasion index corresponds to the ratio of the 
number of cells invading the gel over the total 
number of cells counted in each field16. Re-
combinant human leptin was from R&D Sys-
tems Europe Ltd. (Oxon, UK). Purified recombi-
nant human TFF1 and TFF3 were provided by 
Dr. Lars Thim and Pr. Bruce Westley.  
Cell Proliferation and Tumor Growth Assays 
 Parental and stable HCT8/S11-IB  cells 
were plated at the density of 25,000 cells into 
six-well tissue culture dishes supplemented with 
10% FBS. At the time indicated, cancer cells 
were trypsinized, collected in 1 ml of medium, 
and counted by a Cell Coulter. Six-week-old 
athymic NMRI female nude mice (nu/nu, Ele-
vage Janvier, France) were housed in filtered-
air laminar flow cabinets and handled under 
aseptic conditions. Procedures involving ani-
mals and their care were conducted in con-
formity with Institutional guidelines that are in 
compliance with FMHS, national and interna-
tional laws and policies. Parental and stable 
HCT8/S11-IB  cells were injected s.c. into the 
lateral flank of athymic nu/nu mice (3 X 106 
cells in each xenograft, 7 to 8 animals in each 
group). Tumor volume (V) was calculated us-
ing the formula: V = 0.4 x a x b2, with "a" being 
the length and "b" the width of the tumor. Tu-
mor dimensions were measured with calipers 
every week for 9 weeks. Then, animals were 
sacrificed and the tumors excised, weighed 
and fixed for immuno-histochemical analysis. 
For the immunohistochemical determination 
of the proliferating, five micrometer paraffin-
embedded tissue sections were deparaf-
finized, microwaved during 5 min for antigen 
retrieval, and then incubated with the mouse 
mAb against Ki-67 antigen (DAKO, Copenha-
gen, Denmark, clone MIB-1, dilution 1:50) for 
1h at room temperature. The samples were 
then washed and incubated with secondary 
antibody for 1h at room temperature, followed 
by incubation with the streptavidin-peroxidase 
complex. Ten high-power fields (0.159 mm2) 
per section from 4-5 tumor specimens of each 
group were examined microscopically. The 
average number of cells that stained positive 
for Ki-67 was evaluated in established control 
and IkB -transfected HCT8/S11 xenografts.  
Statistical Analysis 
 Data are means ± SEM for the number of 
experiments indicated. The statistical signifi-
THE NF-B INHIBITOR Journal of Medical Sciences (2010); 3(1) 
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cance between experimental values was as-
sessed by the unpaired Student's t-test and P < 
0.05 was considered to be statistically signifi-
cant. 
RESULTS  
Functional Expression of the IB- Transgene in 
HCT8/S11 Cells 
 First, we examined the impact of the NF-B 
inhibitor IB on the activity of the NF-B re-
porter gene in HCT8/S11 human colon cancer 
cells. Transient transfections were performed 
using the pSGT-srcY572F vector encoding the 
oncogene src, together with the luciferase 
gene reporter construct driven by the NF-B -
dependent promoter. We have previously 
shown that this HCT8/S11 cell line exhibits a low 
level of src activity17. Consistently, introduction 
of the src oncogene induced a robust NF-B 
activation (6.3 -fold) in HCT8/S11 cells, as 
compared with co-transfections performed 
with the control empty vector pSGT (Fig. 1A). 
As expected from previous studies showing the 
implication of src in NF-B activation induced 
by the stress signals hypoxia and reactive oxy-
 
Fig. (1).   down-regulates NF-B promoter activity and wound healing in HCT8/S11 cells.  
A. Reversion by  of src-induced NF-B promoter transactivation. Human cancer cells HCT8/S11 were 
transiently transfected by luciferase reporter constructs driven by the NF-B -dependent promoter, alone or 
combined with expression vectors encoding src alone or combined with the intrinsic NF-B inhibitor IB. 
Data are means ± SEM of 3 independent experiments. B. Wounds were introduced in confluent monolayers 
of parental and stably transfected HCT8/S11- IB  cells. Cells were then cultured at 37°C for 4, 6 and 48 h. 
The mean distance that cells traveled from the edge of the scraped area was measured in a blinded fash-
ion, using an inverted microscope (4 x magnifications, insets). Data are means ± SEM of 3 independent ex-
periments. 
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gen species, as well as cellular adhesion to 
extracellular matrix components18, over-
expression of IB abrogated the direct acti-
vation of NF-B induced by the src oncogene 
in HCT8/S11 cells.  
 Thus, our data validate the functional inser-
tion of IB in our HCT8/S11 model and en-
couraged us to establish a stably transfected 
HCT8/S11 cell line expressing high levels of the 
endogenous NF-B inhibitor IB. The resulting 
cell line was designated HCT8/S11- IB. Ex-
pression of the tagged IB transgene  was 
confirmed by western blot (not shown).  
Impact of IB  on Cancer Cell Migration, Inva-
sion, Proliferation, and Tumor Xenograft 
Growth 
 We next examined the effect of IB ec-
topic expression on cellular migration in HCT8/ 
S11 cells. Using wound-healing experiments 
performed on sub-confluent cell cultures, we 
show that IB  inhibited by 29-53% the migra-
tion of HCT8/S11- IB cells during the 4-6h 
short incubation time considered (Fig. 1B, left) 
suggesting that the inhibition of cellular migra-
tion is not due to inhibition of cell proliferation. 
Parental HCT8/S11 cells were able to achieve 
a complete wound healing within 48h, while 
IB  cells were unable to fully colonize the 
wounds at this time period (Fig. 1B, right).  
 Although trefoil factors contribute to the 
immunity and mucosal protection in the nor-
mal gastrointestinal tract, it is now widely ac-
cepted that these secreted regulatory pep-
tides are strongly induced during inflammatory 
diseases and cancer progression 19. In agree-
ment, TFFs play a pejorative role in several 
transforming functions associated with the 
neoplastic progression in cancer cells and 
tumors, including cellular scattering and inva-
sion, survival and protection against anoïkis-
apoptosis, adenoma-adenocarcinoma transi-
tion, and angiogenesis20 ,21. Indeed, we have 
previously shown that trefoil factors (TFF) and 
leptin induce the invasive phenotype in 
HCT8/S11 cells cultured on collagen type I 
gels14 ,15. As shown in Fig. 2, the leptin invasive 
phenotype was not affected by IB, while this 
NF-B inhibitor selectively impaired the invasive 
responses elicited by the trefoil factors TFF1 
and TFF3. To test the ability of IB to interfere 
with cancer cell proliferation, parental 
HCT8S/S11 cells and their IB transfected 
counterparts were compared for their growth 
rates. As shown in Fig. 3A, HCT8/S11- IB cells 
 
Fig. (2). IB  ectopic expression selectively negates cellular invasion induced by pS2/TFF1 and intestinal 
trefoil factor /TFF3 in HCT8/S11 cells.  
Cellular invasion induced by leptin (100 ng/ml), TFF1 (100nM) and TFF3 (100nM) was measured in parental 
HCT8/S11 cells (control) and stably transfected HCT8/S11- IB  cells. Data are means ± SEM of 3 independ-
ent experiments. 
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exhibit slower proliferation rates, as shown at 
days 4 and 5 in culture (24 and 31 % inhibition, 
respectively). This interesting data prompted 
us to investigate the impact of IB ectopic 
expression on the growth of HCT8/S11 human 
colon tumor xenografts in immunodeficient 
mice. As shown in Fig. (3B), IB ectopic expre-
ssion led to significant inhibition (45%) of tumor 
growth at week 9 following heterotransplanta-
tion.  
 To test the role of IB on tumor cell prolif-
eration in HCT8/S11 human colon xenografts, 
we performed a complementary study on the 
nuclear antigen Ki-67 by immunohistochemis-
try. This nuclear Ki-67 antigen, which is present 
in all phases of the cell cycle, except the Go 
phase, is considered as a classical marker in 
cells engaged in the cell proliferation cycle. 
There was a significant decrease in the mean 
number of Ki-67-positive cells in HCT8/S11- IB 
tumor xenografts (41.8 +/- 3.8 % vs. 65.8 +/- 4.6 
%, P < 0.05), as compared to the controls at 9 
weeks (Fig. 3C). Thus, the inhibition of tumor 
xenografts growth induced by IB appears to 
  
 
Fig. (3). Impact of I ectopic expression on the proliferation of HCT8/S11 cancer cells in culture and on 
tumor xenografts in athymic mice.  
A. HCT8/S11 and HCT8/S11 IB stably transfected cells were seeded into six-well tissue culture dishes (25,000 
cells /dish). Parental and IB -stably transfected cells were counted daily for 4 days. Data are means ± SEM 
of 3 independent experiments. B. Tumor growth assay in immunodeficient mice injected S.C. with HCT8/S11 
or HCT8/S11-IB  cells (*P < 0.05 versus HCT8/S11 xenografts). C. Immunohistochemical staining for Ki-67 
expression in the corresponding HCT8/S11 and HCT8/S11-IB  human colon cancer xenografts. Data are 
means ± SEM of 3 independent experiments. Note differences in Ki-67 proliferation signals between 
HCT8/S11 and HCT8/S11-IB  human colon cancer xenografts (*P < 0.05 versus HCT8/S11 xenografts) 
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be due, at least in part, to a direct effect on 
tumor cell proliferation.  
Discussion 
 Deregulated and constitutive activation of 
cell proliferation and survival signals constitute 
a critical mechanism underlying tumor devel-
opment and cancer progression. Evidence 
suggests that aberrant activation of NF-B and 
its downstream signaling pathways is responsi-
ble for the initiation of tumorigenesis including 
evasion from apoptosis, malignant transforma-
tion, sustained cell proliferation, metastasis, 
and angiogenesis22. A sustained activation of 
NF-B contributes to the expression of proto-
oncogenes c-myc and cyclin D1, which are 
responsible for both transformation initiation 
and tumorigenic proliferation22.  
 In the present study, we have shown that 
ectopic expression of the intrinsic NF-B inhibi-
tor IB   strongly inhibits NF-B transactivation 
directly induced by src oncogene in HCT8/S11 
human colon cancer cells. The src oncogene 
is known to be activated during the early and 
late stages of the neoplastic progression in 
human colon tumors23. Consistently, we dem-
onstrated that blockade of the NF-B path-
ways by IB  led to the invalidation of several 
transforming functions in HCT8S/11 cells. We 
have shown that IB ectopic expression re-
duced the ability of HCT8/S11 cells to prolifer-
ate in vitro and in vivo as tumor xenografts in 
immunodeficient mice. Convergent data and 
reports also revealed that alterations in the 
adhesive properties of cancer cells are asso-
 
 
Fig. (4). Diagram summarizing the NF-  pathway in a cancer cell before (A) and following transfection with 
IB   (B). Over-expression of IB by stable transfection titrates IKKs out, leaving some IB in the ternary com-
plex unphosphorylated. This will prevent NF- nuclear translocation and thus maintaining a constitutive 
repression of the NF-B responsive genes. 
A)
B)
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ciated with invasive growth and tumor malig-
nancy (data summarized in Fig. 4). Cellular 
adhesion to ECM components via their in-
tegrin receptors, intercellular adhesion, and 
activation of the actomyosin system in the 
cytoskeleton are known to play pivotal roles in 
the integration of the mechanisms leading to 
directed cellular movements during wound 
healing assays. Loss of E-cadherin and other 
intercellular adhesion molecules also correlate 
with cancer cell scattering, migration, and 
tumor cell invasion23. This loss of cell-cell adhe-
sion appears to be a key event in acquisition 
of the invasive potential, because re-
expression of E-cadherin suppresses the inva-
sive growth of human tumors24 ,25. Consistently, 
it has been shown that NF-B pathway can 
suppress E-cadherin expression via specific 
transcription repressors such as Snail, an NF-B 
target gene 26 ,27. Snail-induced E-cadherin loss 
and epithelial-mesenchymal transitions (EMT) 
are associated with the invalidation of the 
epithelial cell polarity, stimulation of cancer 
cell proliferation, and exacerbation of the in-
vasive and metastatic potential in clinical hu-
man epithelial tumors28 ,29. Similarly, integrin 
ligation to ECM components was shown to 
activate the transcription factor NF-B in mul-
tiple cell types18. Given the role of the NF-B 
inhibitor IB  in inhibiting HCT8/S11 cell migra-
tion in the present study, one can postulate 
that this pathway has potential roles in the 
regulation of intercellular and cell-matrix ad-
hesion mechanisms, as well as activation of 
the cytoskeleton during cancer cell migration 
and invasion. In coherence with this predic-
tion, we have shown here that IB  ectopic 
expression selectively negated HCT8/S11 can-
cer cell invasion induced by TFF1 and TFF3, but 
not by leptin, in collagen type I gels. Consis-
tently, several studies indicate that both TFF 
expression and biological activities are con-
trolled by NF-B since several NF-B binding 
sites are localized in the promoter regions of 
the three TFF genes19 ,29. In contrast, blockade 
of the NF-B pathways is not associated with 
the reversion of the leptin invasive potential in 
our study, suggesting that alternative proinva-
sive pathways induced by this cytokine are still 
operational under NF-B blockade. Indeed, 
several studies have identified the multiplicity 
of the leptin receptor signaling networks con-
nected with cancer cell invasion and tumor 
angiogenesis. These include the PI3-kinase 
/AKT axis, MAPK ERK1/2 cascade, the Rho-
GTPases, the JAK2 /STAT3 transcription signals, 
as well as several crosstalks engaged with 
other transmembrane receptors14. These ca-
nonical and alternative leptin pathways are 
inherent to cancer cell proliferation, survival, 
invasion and metastasis, as well as tumor an-
giogenesis and metastasis. 
 We propose that the NF-B oncogenic 
pathway can be targeted to halt tumor inva-
sive growth and progression to the metastatic 
stages. Several studies have addressed the 
design of putative NF-B inhibitors as pharma-
cologic therapeutic agents in cancer patients. 
Anti-inflammatory drugs and natural com-
pounds, such as curcumin and transveratrol, 
inhibit NF-B by interfering with IKK activity30. 
Finally, proteasome inhibitors were also shown 
to prevent NF-B activation by blocking the 
degradation of IB. In summary, the results of 
our study provide new insight into the devel-
opment of therapeutic strategies against co-
lon cancer promotion and progression, using 
NF-B interfering drugs in combinations with 
other anticancer agents targeting selected 
oncogenic pathways or genotoxins that dis-
rupt the functional integrity of the DNA.  
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